OVERVIEW

Community Practice Connections™: 1st Annual Precision Medicine Symposium: An Illustrated Tumor Board is organized by Physicians' Education Resource, LLC (PER).

Release Date: June 30, 2019
Expiration Date: June 30, 2020

Target Audience:
This educational activity is directed toward pathologists and oncologists, as well as nurses and fellows involved in the treatment and management of patients with cancers. Physician assistants, pharmacists, researchers, and other healthcare professionals may also participate.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Activity Overview:
This activity, featuring program chair Andre H. Goy, MD, MS; Corey J. Langer, MD; Andrew L. Pecora, MD, CPE; and Andrew Norden, MD, MPH, MBA, describes the state of the art in the treatment of lymphomas and of the cancer responsible for more annual deaths than any other—lung cancer. This program describes current practices in the classification of lymphomas and predictors of survival in lymphoma, as well as current treatment options. Emerging treatment options across lymphomas, including use of immunotherapy following transplant, are also discussed. In lung cancer, the integration of targeted therapy and checkpoint inhibitor therapy into treatment are reviewed, with a discussion of adverse event management strategies and perspectives on managing costs in the present era of ever-changing cancer care strategies.

Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Examine clinical studies in common malignancies and examine relevant biomarkers to select patients for therapy.
• Utilize tumor pathology assessment reports to enable evidence-based treatment of malignancies.
• Optimize diagnosis and management of malignancies through multidisciplinary cooperation.
• Describe the current and evolving role of genomic assays in cancer management.
• Identify potential applications of liquid biopsy in the assessment of commonly encountered malignancies.

Additional details will be posted as soon as information is available.